[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100519175":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":25,"centralContacts":29,"locations":34,"responsibleParty":71,"collaborators":74,"id":77,"slug":24,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":24,"eligibilityCriteria":81,"healthyVolunteers":78,"sex":82,"minAge":83,"maxAge":24,"enrollmentInfo":84,"targetDuration":24,"studyType":87,"phases":88,"briefSummary":90,"conditions":91,"keywords":95,"overallStatus":56,"whyStopped":24,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"Dana-Farber Cancer Institute","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Exercise Group","EXPERIMENTAL","Participants will partake in a 16-week supervised exercise program.",[13],"Behavioral: Supervised Circuit Training",{"label":15,"type":10,"description":16,"interventionNames":17},"Attention Control Group","Participants will continue with their normal daily activities.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"BEHAVIORAL","Supervised Circuit Training","16-week, multicomponent exercise intervention comprised of sessions supervised by certified exercise oncology trainer and home-based, self-directed aerobic exercises. Stationary bike and accelerometer (activity\u002Fheart rate monitor) will be provided.",[15,9],null,[26],{"name":27,"affiliation":5,"role":28},"Christina Dieli-Conwright, MD","PRINCIPAL_INVESTIGATOR",[30],{"name":27,"role":31,"phone":32,"phoneExt":24,"email":33},"CONTACT","617-582-8321","ChristinaM_Dieli-Conwright@dfci.harvard.edu",[35,54,65],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Beth Israel Deaconess Medical Center","NOT_YET_RECRUITING","Boston","Massachusetts","02215","United States",{"type":43,"coordinates":44},"Point",[45,46],-71.05977,42.35843,{"lat":46,"lon":45},[49,53],{"name":50,"role":31,"phone":51,"phoneExt":24,"email":52},"David Einstein, MD","617-667-1957","Deinstei@bidmc.harvard.edu",{"name":50,"role":28,"phone":24,"phoneExt":24,"email":24},{"facility":55,"status":56,"city":38,"state":39,"zip":40,"country":41,"cosmosGeoPoint":57,"geoPoint":59,"contacts":60},"Brigham and Women's Hospital","RECRUITING",{"type":43,"coordinates":58},[45,46],{"lat":46,"lon":45},[61,64],{"name":62,"role":31,"phone":32,"phoneExt":24,"email":63},"Christina Dieli-Conwright, PhD, MPH","ChristinaM_Dieli-Conwright@DFCI.HARVARD.EDU",{"name":62,"role":28,"phone":24,"phoneExt":24,"email":24},{"facility":5,"status":37,"city":38,"state":39,"zip":40,"country":41,"cosmosGeoPoint":66,"geoPoint":68,"contacts":69},{"type":43,"coordinates":67},[45,46],{"lat":46,"lon":45},[70],{"name":27,"role":31,"phone":32,"phoneExt":24,"email":33},{"type":28,"investigatorFullName":72,"investigatorTitle":73,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"Christina Dieli-Conwright, PhD","Principle Investigator",[75],{"name":76,"class":6},"Prostate Cancer Foundation","100519175",false,"NCT06040125","Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE Trial","Inclusion Criteria:\n\n* Ability to understand and the willingness to sign informed consent prior to any study-related procedures.\n* Diagnosed with metastatic prostate cancer.\n* Aged ≥18 years; due to the rarity of the disease in those \\\u003C18 years, this age bracket will not be included.\n* Have been receiving androgen deprivation (either with or without androgen receptor targeted treatment) for at least one month and expect to remain on their treatment for at least 4 months.\n* Are pre-frail or frail as indicated by the FRAIL scale (a score of 1-2 = pre-frail; 3-5 = frail).\n* Have physician's clearance to participate in exercise.\n* Speak English.\n* Participate in less than 2 structured resistance exercise sessions per week over the last 4 months.\n* Participate in less than or equal to 60 minutes of moderate-to-vigorous aerobic exercise per week over the last month.\n* Willing to travel to Dana-Farber Cancer Institute for necessary data collection and exercise sessions.\n\nExclusion Criteria:\n\n* Receiving chemotherapy. This study is exclusively targeting androgen deprivation therapy-related effects.\n* Have unstable bone lesions. In general patients with severely symptomatic\u002Funstable bone lesions due to bone metastases are at a higher risk of fractures.\n* Complete 2 or more structured resistance exercise sessions per week over the last 4 months and participate in more than 60 minutes of moderate-to-vigorous aerobic exercise per week over the last month. Excess additional exercise is a confounding factor in assessing the effect of the current exercise program.\n* Unstable comorbidities that prevent participation in moderate-to-vigorous intensity exercise. Patients with unstable comorbidities likely require supervised exercise for safety, and part of this study involves unsupervised exercise; therefore, for safety reasons, these persons are excluded.\n* Patients receiving treatment for other active malignancies (except basal cell carcinoma). This study is exclusively targeting androgen deprivation therapy-related effects.\n* Subjects who in the opinion of the investigators may not be able to comply with the safety monitoring requirements of the study.","MALE","18 Years",{"count":85,"type":86},80,"ESTIMATED","INTERVENTIONAL",[89],"NA","The purpose of this study is to determine whether a 16-week supervised, clinic-based circuit training intervention utilizing resistance and functional exercises and self-directed aerobic exercise will improve frailty and sarcopenic status and disease progression outcomes among pre-frail\u002Ffrail metastatic prostate cancer patients receiving androgen deprivation therapy (ADT).\n\nThe names of the study intervention involved in this study is:\n\n• Supervised circuit training (aerobic and resistance exercise regimen)",[92,93,94],"PROSTATE CANCER","Metastatic Prostate Cancer","Metastatic Prostate Carcinoma",[96,93,94],"Prostate Cancer","2026-03-10",{"date":99,"type":100},"2026-03-11","ACTUAL",{"date":102,"type":100},"2024-01-01",{"date":104,"type":86},"2027-02-28",{"name":5,"class":6},3]